|Bid||3.1500 x 800|
|Ask||0.0000 x 1800|
|Day's Range||3.7500 - 4.0000|
|52 Week Range||3.1050 - 11.9300|
|Beta (5Y Monthly)||1.24|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 09, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.64|
This article will reflect on the compensation paid to Richard Chin who has served as CEO of Kindred Biosciences, Inc...
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will present at the Stifel Virtual Healthcare Conference on November 17 and participate in the A.G.P. Virtual Healthcare Symposium on November 19.
Kindred Bio (KIN) delivered earnings and revenue surprises of 0.00% and 82.98%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?